Related Experiment Video
Updated: May 12, 2025
04:05
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
298
Efficacy And Safety of Acupoint Catgut Embedding for Perennial Allergic Rhinitis: Protocol for a Randomized Clinical
Zijie Cai1, ChunXue Meng2, Fei Wang2
1Guangdong International Clinical Research Center of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China.
JMIR Research Protocols
|April 21, 2025
Summary
Acupoint catgut embedding (ACE) therapy is being evaluated for allergic rhinitis (AR) in a rigorous clinical trial. This study aims to provide robust evidence on the efficacy and safety of ACE for AR management.
Area of Science:
- Allergy and Immunology
- Traditional Chinese Medicine
- Clinical Trials
Background:
- Allergic rhinitis (AR) is a prevalent chronic inflammatory nasal condition affecting millions globally.
- Current treatments offer limited long-term efficacy and can have side effects.
- Acupoint catgut embedding (ACE) therapy is a common treatment for AR in China, but requires further validation.
Purpose of the Study:
- To evaluate the efficacy and safety of Acupoint Catgut Embedding (ACE) therapy for Allergic Rhinitis (AR).
- To provide robust data through a high-quality, multicentered, randomized controlled trial.
Main Methods:
- A parallel-arm, patient-blind, placebo-controlled randomized trial.
- Participants will be randomized to either ACE therapy or sham ACE therapy.
- Both groups will receive conventional loratadine treatment over a 4-week period with a 3-month follow-up.
Main Results:
- Study funding initiated January 2022.
- Trial initiated February 1, 2025, concluding February 2026.
- Patient recruitment is ongoing; results anticipated March 2026.
Conclusions:
- This research is expected to yield significant insights into ACE therapy for AR.
- The study aims to generate robust data to support future research and clinical practice.
